← FDA DRUG APPROVALS

FDA ANDA · ANDA076569

NICOTINE POLACRILEX MINT

nicotine polacrilex

Sponsor: P AND L

APPLICATION
ANDA076569
TYPE
ANDA
ORIGINAL APPROVAL
2004-07-29
LATEST ACTION
2017-04-11
ROUTE
BUCCAL, ORAL
DOSAGE FORM
GUM, CHEWING
MARKETING STATUS
Over-the-counter, Discontinued

Products

NICOTINE POLACRILEXOver-the-counter
NICOTINE POLACRILEX EQ 2MG BASE · GUM, CHEWING · BUCCAL
NICOTINE POLACRILEXDiscontinued
NICOTINE POLACRILEX EQ 4MG BASE · GUM, CHEWING · BUCCAL

Approval history

2017-04-11Labeling · Supplement 27 · standardAP
2015-04-30Labeling · Supplement 23 · standardAP
2013-01-28Labeling · Supplement 21 · standardAP
2007-07-23Labeling · Supplement 8AP
2006-12-08Labeling · Supplement 3AP
2005-04-22Labeling · Supplement 1AP
2004-07-29OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →